Search for a report

NORTH AMERICA INFLUENZA VACCINE MARKET FORECAST 2020-2028

  • You are here:
  • Home
  • Downloads
  • NORTH AMERICA INFLUENZA VACCINE MARKET FORECAST 2020-2028

NORTH AMERICA INFLUENZA VACCINE MARKET FORECAST 2020-2028

The North American influenza vaccine market is estimated to grow at a CAGR of 6.06% during the forecast period of 2020-2028. One of the crucial factors propelling the market growth in the region is the government immunization program to get rid of ailments from society. In order to understand the growth of the North America influenza vaccine market, the region is divided into the United States and Canada.

NORTH AMERICA INFLUENZA VACCINE MARKET FORECAST 2020-2028

North America Influenza Vaccine Market by Type (Quadrivalent Vaccine, Trivalent Vaccine) by Technology (Egg-based Technology, Cell-based Technology) by Age Group (Pediatric Age Group, Adult Age Group)  by Delivery Mode (Injection, Asal Spray) and by Geography.

Request free sample

The North American influenza vaccine market is estimated to grow at a CAGR of 6.06% during the forecast period of 2020-2028. One of the crucial factors propelling the market growth in the region is the government immunization program to get rid of ailments from society.

In order to understand the growth of the North America influenza vaccine market, the region is divided into the United States and Canada. ACIP is a group of experts of medical and public health that works on developing recommendations on the use of vaccines in the U.S. According to a data published by the government body, CDC, the number of deaths due to influenza were in between 32,000-51,000, hospitalizations were 290,000 and medical visits were 10 million in 2010-2011. However, in 2018, the number of deaths due to influenza increased to 69,000-99,000, hospitalizations were 0.96 million, and medical visits were 23 million. A surge in the prevalence of influenza and a rise in awareness, and the number of vaccines required per person, are expanding market growth. Furthermore, the recommended doses as per individual recommended by CDC, the discussions by the HHS and ACIP on vaccine research and development of vaccine technology, supplement market growth. At present, the hospitalization rates due to influenza remain moderate for the overall U.S. population, but the rates for children between 0-4 years and adults 18-49 years are the highest. The rates for hospitalization of school children aged between 5-17 years remain higher than any regular season, but are lower than rates during the pandemic.

Merck is a healthcare manufacturer and distributor of pharmaceuticals, operating in the pharmaceutical, healthcare services, animal health, and alliances.

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES `
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • PARENT MARKET ANALYSIS: VACCINE MARKET
      • MARKET DEFINITION
      •    KEY DRIVERS
        • GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
        • RISE IN THE CASES OF INFLUENZA
        • TECHNOLOGY ADVANCEMENT
      •    KEY RESTRAINTS
        • HIGH COST OF DEVELOPMENT
        • LENGTHY PROCESS OF DEVELOPMENT
    1. KEY ANALYTICS
      • KEY INVESTMENT INSIGHTS
      •    PORTER’S FIVE FORCE ANALYSIS
        • BUYER POWER
        • SUPPLIER POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    2. MARKET BY TYPE
      • QUADRIVALENT VACCINE
      • TRIVALENT VACCINE
    3. MARKET BY TECHNOLOGY
      • EGG-BASED TECHNOLOGY
      • CELL-BASED TECHNOLOGY
    4. MARKET BY AGE GROUP
      • PEDIATRIC AGE GROUP
      • ADULT AGE GROUP
    5. MARKET BY DELIVERY MODE
      • INJECTION
      • NASAL SPRAY
    6. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. COMPANY PROFILES
      • MERCK
      • NOVARTIS AG
      • PFIZER INC
      • SANOFI
      • BIODIEM
      • EMERGENT BIOSOLUTIONS
      • HOFFMANN-LA ROCHE LTD
      • GLAXOSMITHKLINE
      • ABBOTT
      • CSL LTD

    TABLE LIST

    TABLE 1: MARKET SNAPSHOT – INFLUENZA VACCINE

    TABLE 2: NORTH AMERICA INFLUENZA VACCINE MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 3: NORTH AMERICA INFLUENZA VACCINE MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 4: NORTH AMERICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 5: NORTH AMERICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 6: NORTH AMERICA INFLUENZA VACCINE MARKET, BY AGE GROUP, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 7: NORTH AMERICA INFLUENZA VACCINE MARKET, BY AGE GROUP, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 8: NORTH AMERICA INFLUENZA VACCINE MARKET, BY DELIVERY MODE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 9: NORTH AMERICA INFLUENZA VACCINE MARKET, BY DELIVERY MODE, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    TABLE 10: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

    TABLE 11: NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)

    FIGURE LIST

    FIGURE 1: KEY INVESTMENT INSIGHTS

    FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: NORTH AMERICA INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2019

    FIGURE 6: NORTH AMERICA INFLUENZA VACCINE MARKET, BY QUADRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

    FIGURE 7: NORTH AMERICA INFLUENZA VACCINE MARKET, BY TRIVALENT VACCINE, 2020-2028 (IN $ MILLION)

    FIGURE 8: NORTH AMERICA INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2019

    FIGURE 9: NORTH AMERICA INFLUENZA VACCINE MARKET, BY EGG-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

    FIGURE 10: NORTH AMERICA INFLUENZA VACCINE MARKET, BY CELL-BASED TECHNOLOGY, 2020-2028 (IN $ MILLION)

    FIGURE 11: NORTH AMERICA INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2019

    FIGURE 12: NORTH AMERICA INFLUENZA VACCINE MARKET, BY PEDIATRIC AGE GROUP, 2020-2028 (IN $ MILLION)

    FIGURE 13: NORTH AMERICA INFLUENZA VACCINE MARKET, BY ADULT AGE GROUP, 2020-2028 (IN $ MILLION)

    FIGURE 14: NORTH AMERICA INFLUENZA VACCINE MARKET, GROWTH POTENTIAL, BY DELIVERY MODE, IN 2019

    FIGURE 15: NORTH AMERICA INFLUENZA VACCINE MARKET, BY INJECTION, 2020-2028 (IN $ MILLION)

    FIGURE 16: NORTH AMERICA INFLUENZA VACCINE MARKET, BY NASAL SPRAY, 2020-2028 (IN $ MILLION)

    FIGURE 17: NORTH AMERICA INFLUENZA VACCINE MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

    FIGURE 18: UNITED STATES INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    FIGURE 19: CANADA INFLUENZA VACCINE MARKET, 2020-2028 (IN $ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      •    NORTH AMERICA
        • UNITED STATES
        • CANADA
    1. MARKET BY TYPE
      • QUADRIVALENT VACCINE
      • TRIVALENT VACCINE
    2. MARKET BY TECHNOLOGY
      • EGG-BASED TECHNOLOGY
      • CELL-BASED TECHNOLOGY
    3. MARKET BY AGE GROUP
      • PEDIATRIC AGE GROUP
      • ADULT AGE GROUP
    4. MARKET BY DELIVERY MODE
      • INJECTION
      • NASAL SPRAY

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now